BioPact CEO Kent Phelps presents at UMass as finalist in the 2015 M2D2 New Venture Competition
On April 1st, M2D2 held a live pitch-off event featuring 15 early-stage medical companies vying for $100,000 in prizes. The international competition showcased ideas from young medical device companies and will provide winners with mentorship and funding. The audience of over 300 included media, investors, inventors, physicians and business professionals.
In his presentation (limited to 4 minutes), Kent noted the long wait for truly medical grade carbon nanotubes to arrive on the scene. He explained how BioPact’s Medical Grade Molecular Rebar, or MGMR, fulfills the long awaited promise of non-cytotoxic, length-controlled, scalable carbon nanotubes in targeted drug delivery, diagnostics and devices.
Kent noted the world class team assembled to take this technology into the global medical marketplace – bio chemists out of MIT, St. Jude’s Children’s Hospital and Dana Farber Cancer Institute. Business development professionals and scientists from Big Pharma companies like Amgen, Sanofi and Merck. Former DOW chemical scientists and executves. And a team of top IP attorneys to protect BioPact’s expanding portfolio of issued and pending patents.
Kent focused on the benefits of MGMR to cancer patients. Specifically, MGMR’s ability to reduce toxicity of and stabilize cancer drugs too potent to take to market. It was noted that the MGMR breakthrough will breathe new life into sidelined cancer drugs, improving quality of life and survival rates of cancer patients.
Win or lose, BioPact is grateful to the folks at M2D2 for the opportunity to participate in this well organized and executed competition!